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ABSTRACT 
 
Background. We sought to determine whether skeletal muscle oxidative capacity, fiber 
type proportions and fiber size, capillary density or muscle mass might explain the 
impaired exercise tolerance in chronic heart failure (CHF). Previous studies are equivocal 
regarding the maladaptations that occur in the skeletal muscle of patients with CHF and 
their role in the observed exercise intolerance. 
 
Methods and Results. Total body O2 uptake ( peak) was determined in 14 CHF 
patients and 8 healthy sedentary similarly-aged controls. Muscle samples were analysed 
for mitochondrial ATP production rate (MAPR), oxidative and glycolytic enzyme 
activity, fiber size and type, and capillary density. CHF patients demonstrated a lower 
peak (15.1 ± 1.1 vs. 28.1 ± 2.3 ml.kg
&VO2
&VO2 -1.min-1, p<0.001) and capillary to fiber ratio 
(1.09 ± 0.05 vs. 1.40 ± 0.04; p<0.001) when compared to controls. However there was no 
difference in capillary density (capillaries per µm2) across any of the fiber types. 
Measurements of MAPR and oxidative enzyme activity indicated no difference in muscle 
oxidative capacity between the groups. Conclusions. Neither reduced muscle oxidative 
capacity nor capillary density are the cause of exercise limitation in CHF patients. We 
conclude that the low peak observed in CHF patients is the result of muscle fiber 
atrophy and possibly impaired activation of oxidative phosphorylation. 
&VO2
KEY WORDS: Exercise Capacity, Skeletal Muscle 
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INTRODUCTION 
 
Compared to healthy subjects, patients with chronic heart failure (CHF) exhibit a reduced 
exercise tolerance characterised by a low peak oxygen consumption ( &VO2 peak) and the 
early onset of fatigue 1 and lactic acidosis 2 during incremental exercise. These symptoms 
were formerly considered to be due to impaired cardiac function in these patients. There 
is no correlation, however, between &VO2 peak and indices of left ventricular performance 
3. Further, in CHF patients the addition of arm exercise to maximal leg exercise produces 
increases in &VO2 peak suggesting that exercise capacity in these subjects is limited by 
muscle function not cardiac output 4.  
 
We have previously observed deficits in exercise tolerance in lung transplant recipients 5 
similar to those described above for CHF patients. The vastus lateralis muscles of the 
lung transplant recipients exhibited a range of abnormalities which potentially 
contributed to their reduced exercise capacity. These abnormalities included reduced 
levels of oxidative enzymes, a reduced proportion of type I muscle fibers and, 
significantly, lowered mitochondrial ATP production rates (MAPR). The exercise 
intolerance in CHF has also been attributed to maladaptations in skeletal muscle such as 
reduced oxidative capacity, altered muscle fiber type composition and fiber atrophy or 
loss leading to reduced muscle strength 6-9. It is also possible that reduced muscle blood 
flow is also an important component in exercise impairment in these patients 8. 
 
The effects of CHF on skeletal muscle oxidative capacity are unclear. Whilst most reports 
have suggested reduced activity of oxidative enzymes, this is not universally the case. 
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Sullivan et al. 10 report reductions in both CS and SDH activity in CHF patients while 
Opasich and colleagues 29 reported no difference in either of these enzymes in their CHF 
group. Other similar studies have reported significant reductions in some but not all 
oxidative enzymes measured 11,13,14.   Interestingly, studies examining the effects of CHF 
on oxidative phosphorylation in vivo have consistently reported reduced rates of oxidative 
phosphorylation in CHF patients 27,28. The anomalies alluded to above notwithstanding; 
reduced exercise tolerance has therefore been attributed to reduced muscle oxidative 
capacity. The rate of ATP production is a very sensitive test of mitochondrial function in 
skeletal myocytes 19. However, no previous studies have examined mitochondrial ATP 
production rates (MAPR) in CHF patients. 
 
The aim of the present study was to determine the role of skeletal muscle histochemical 
and metabolic maladaptations to CHF. In particular, we hypothesized that, compared to 
sedentary similarly aged healthy controls, the skeletal muscle of CHF patients would 
exhibit lower MAPR, and that this would be associated with a higher proportion of 
glycolytic fibers, muscle fiber atrophy and lower capillary density.   
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MATERIALS AND METHODS 
Subjects. Fourteen stable chronic heart failure (CHF) patients (13 male/1 female; 68 ± 9 
years, 84 ± 15 kg, body mass index 28 ± 5 kg/m2; mean ± S.D.) and eight healthy 
sedentary control subjects (7 male/1 female; 63 ± 11 years, 78 ± 8 kg, body mass index 
26 ± 3 kg/m2) participated in this study. The CHF group were in New York Heart 
Association functional class (NYHA) II (n = 11) & III (n = 3) and had left ventricular 
ejection fractions (LVEF) of 27 ± 8%. The average time since diagnosis of CHF in the 
patients was 39 ± 41 months. Two of the 14 CHF patients were current smokers while all 
healthy subjects were non-smokers. Diagnoses and medications for the CHF patients are 
presented in Table 1. Control subjects were healthy sedentary individuals with no history 
of left ventricular dysfunction. Written informed consent was obtained from all subjects 
prior to their entry into this study which was approved by the Human Research Ethics 
Committees of The Austin and Repatriation Medical Centre and Victoria University of 
Technology. The investigation conforms to the principles outlined in the Declaration of 
Helsinki. 
 
Incremental Exercise Tests and blood sampling. Peak total body oxygen consumption 
( peak&VO2 ) was determined on CHF patients during a symptom-limited graded exercise 
test on an electronically braked bicycle ergometer (Ergomed, Siemens, Erlangen, 
Germany), commencing at 10 W and increasing by 10 W.min  to volitional fatigue or 
until symptoms intervened. In the healthy control group, the exercise test commenced at 
20 W and increased by 20 W.min  until a respiratory exchange ratio (RER) of 1.0 was 
reached. Work rate then increased by 10 W.min  until volitional fatigue or a level of 17 
-1
-1
-1
 5
on the 6-20 point Borg scale of perceived exertion . Expired volume and expired 
oxygen and carbon dioxide concentrations were analysed and used to compute oxygen 
consumption ( ), carbon dioxide production ( ) and respiratory exchange ratio 
(RER = / ) as previously described . Arterial oxygen saturation (pulse 
oximetry; Oxi-Radiometer, Boulder, CO) and ECG were monitored continuously 
throughout the test. 
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Blood samples were obtained from a dorsal hand vein via a 20-guage indwelling catheter. 
Arterialisation was maintained by immersion of the hand, covered by a waterproof plastic 
glove, in a water bath maintained at 45oC. Blood samples were drawn at rest, every 
minute during exercise and at 1, 2, 5 and 10 minutes post-exercise for measurement of 
arterial oxygen saturation (SaO2) and plasma lactate concentration. Oxygen saturation in 
the blood samples was consistently in excess of 95%, confirming arterialisation. 
 
Plasma Lactate, Calculation of Lactate Threshold and Predicted &VO2 peak. Plasma 
lactate levels were determined using Roche Diagnostic Kit reagents. Lactate threshold 
was calculated from a log-log transformation plot of plasma lactate concentration vs. 
power output (W). Predicted &VO2 peak was calculated according to the formulae of 
Wasserman et al. 17. 
 
Muscle Strength Testing. Unilateral (right leg) skeletal muscle strength and endurance 
for knee extension / flexion were assessed using an isokinetic dynamometer (MERAC®) 
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(Universal, Cedar Rapids, Iowa, USA), with microprocessor, as previously described 
16,18. 
  
Dual Energy X-ray Absorptiometry (DEXA). 11 of the CHF patients and the 8 healthy 
control subjects underwent total body and thigh DEXA scanning (DXA, Lunar Corp. 
using DPX-L, Version 4.6E software, Madison, WI), using < 0.2 microsieverts, to 
determine body composition including lean tissue mass.  
 
Muscle Biopsy. Approximately seven days after the incremental exercise test, a resting 
muscle biopsy was obtained from the vastus lateralis. For those on anticoagulant 
medications, these were discontinued for four days prior to the biopsy. Following 
injection of a local anaesthetic (2% Lignocaine) into the skin and against the fascia, a 
small incision was made with a scalpel and a muscle sample was taken with a 5mm 
diameter muscle biopsy needle. One portion of muscle (15-20mg) was embedded in 
Tissue Tek mounting medium and immediately immersed in isopentane, cooled in liquid 
nitrogen, and stored in liquid nitrogen for later histochemical analysis. A second piece of 
muscle (15-20mg) was immediately frozen in liquid nitrogen for later analyses of enzyme 
activities. A third piece of fresh muscle (35-40mg) was placed on ice and immediately 
taken to the laboratory for the determination of mitochondrial ATP production rate 
(MAPR). 
 
Mitochondrial Preparation. Fresh muscle was placed on a plate over ice, dissected free 
of visible connective tissue, minced finely with a scalpel blade and then transferred to a 
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ground glass tissue homogenising tube (Kontes, New Jersey) for weighing. The muscle 
was homogenized over ice, with a ground glass pestle, for approximately 5 minutes. The 
homogenising solutions and procedures for the preparation of the mitochondrial 
suspension have been described by Wibom and Hultman 19. 
 
MAPR Measurement. MAPR was determined at 25oC using the method and substrate 
concentrations described by Wibom and Hultman 19 in the presence of the following 
substrate combinations: pyruvate + malate (P+M), palmitoyl-L-carnitine + malate 
(PC+M), α-ketoglutarate (α-kg), succinate + rotenone (S+R) and pyruvate + palmitoyl-L-
carnitine + α-ketoglutarate + malate (PPKM). ATP production by the adenylate kinase 
reaction and other non-specific reactions was determined from a blank containing ADP 
and mitochondrial suspension alone. Details of the procedure for MAPR in the presence 
of these substrates as used in our laboratory have been described previously 5 with the 
exception of the method used to determine mitochondrial yield which is described below. 
All measurements of MAPR were made in duplicate, completed within 4 h of biopsy and 
are expressed as mmol.min-1.kg-1 wet weight of muscle. 
 
Measurement of Citrate Synthase activity. Citrate synthase (CS) is a specific 
mitochondrial marker enzyme and was used to determine mitochondrial yield in the 
suspensions. The activity of CS in intact mitochondria (CSim) was determined from CS 
activity of the mitochondrial suspension before and after mitochondrial disruption. Total 
muscle CS activity (CSt) was determined on a separate piece of muscle homogenized in 
175mM KCl and 2mM EDTA (pH 7.4). All CS activity measurements were performed at 
 8
25oC with spectrophotometric detection (LKB Biochrom, Ultrospec II, Cambridge, 
England) in a reaction mixture containing 100mM Tris buffer (pH 8.3), 1mM DTNB, 
3mM acetyl CoA and 10mM oxaloacetate according to the method of Srere 20. The yield 
of intact mitochondria in the mitochondrial suspension was calculated as the ratio of CSim 
to CSt.   
 
Measurement of other Enzyme Activities. The enzyme activities of the fatty acid β-
oxidative enzyme β-hydroxyacyl coenzyme A dehydrogenase (HAD) and the glycolytic 
enzymes phosphofructokinase (PFK) and lactate dehydrogenase (LDH), were also 
measured. Whole muscle homogenates (1:100 dilution) were prepared on ice in 0.17M 
phosphate buffer at pH 7.4 containing 0.02% bovine serum albumin (BSA) and 5mM 2-
mercaptoethanol according to the method of Green et al. 21. 
 
PFK was assayed on fresh homogenate 21. LDH was assayed on stored homogenate using 
a reaction mixture (pH 7.0) containing 100mM Imidazole, 1.0mM pyruvate, 0.04% BSA 
and 25µM NADH based on the method of Costill et al. 22. HAD was assayed on stored 
homogenate with 150mM Imidazole-HCl buffer (pH 6.0), 1mM EDTA, 200µM S-aceto-
acetyl CoA, 0.05% BSA and 100 µM NADH in the reaction mixture 23. 
 
Histochemistry. For muscle fiber type determinations serial transverse sections (10µm), 
of the previously mounted muscle tissue, were cut in a cryostat (Microm, Heidelberg) at -
20oC. The sections were mounted on coverslips and stained for myofibrillar ATPase at 
pH 9.4 following acid (pH 4.3 and 4.6) and alkaline (pH 10.35) pre-incubations to 
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classify type I, IIA and IIX muscle fibers as has previously been described 24. Additional 
serial cross-sections (16µm) of the muscle were stained for capillary density using the 
periodic acid Schiff-amylase method 25.  
 
Fiber type percentages were determined from sections containing 204 ± 19 (mean ± S.E.) 
fibers. Entire sections stained for capillaries were used to compute capillary to fiber ratio 
(203 ± 13). Mean capillary contacts per fiber type were determined on 20 contiguous 
fibers of each type except where there were insufficient fibers of a particular type. In this 
case capillary contacts for the fiber type were made on the number of fibers of that type 
available. Cross-sectional area measurements of specific fiber types were made using a 
computerized imaging system (Analytical Imaging System, Imaging Research Inc, 1999). 
The mean cross-sectional area (µm2) of each fiber type was computed based on 20 
contiguous fiber areas per type, as recommended by Simoneau and colleagues 26. 
 
Statistical Analysis. Data from patients and control subjects were compared using 
unpaired Student’s t tests for independent variables. Data are expressed as means ± S.E. 
A p value of less than 0.05 was considered significant. Correlations were performed using 
the regression function on Microsoft Excel. 
 
RESULTS 
Exercise Tolerance. Compared with their healthy counterparts CHF patients had 
significantly lower peak oxygen consumption ( &VO2 peak; 15.1 ± 1.1 vs. 28.1 ± 2.3 ml.kg-
1.min-1; p < 0.001) (Table 2). Strength of the quadriceps (p < 0.05) and hamstrings (p < 
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0.01) were also lower in the CHF patient group compared to the healthy control subjects 
(Table 2). The CHF patient group had an earlier lactate threshold (Table 3), occurring at 
30.3 ± 3.5 W versus 81.6 ± 8.6 W for control subjects (p < 0.001), and at termination of 
exercise, exhibited a lower peak work rate (p < 0.01). Lactate threshold when expressed 
as a percentage of peak work rate achieved during the exercise test was lower in the CHF 
group than in the normal subjects (p < 0.01) (Table 3). There was no difference in peak 
RER between the CHF patient group and the control subjects indicating that subjects 
ceased exercise at similar relative exercise intensities. (Table 3). No patient desaturated at 
the termination of exercise.  
 
Muscle Oxidative Capacity. There was no difference in MAPR between the CHF 
patients and the healthy control group for any of the substrate combinations (Figure 1). 
The yield of intact mitochondria used for the MAPR assay was not statistically different 
between the CHF group (19.7 ± 2.2 %) and the healthy subjects (26.1 ± 2.4 %). There 
were no significant differences in the activities of the oxidative enzymes CS and HAD or 
in the activities of the glycolytic enzyme LDH (Table 4). A trend towards significance 
was observed in the glycolytic enzyme PFK (p = 0.12) between CHF patients and healthy 
controls.  
 
Muscle Fiber Types. Histochemical data was obtained from 13 CHF patients and seven 
controls. CHF patients exhibited a lower proportion of type IIA muscle fibers (20.4 ± 2.1 
vs. 35.3 ± 1.9; p < 0.0001) and higher proportion of type IIX muscle fibers (32.6 ± 1.8 vs. 
18.5 ± 1.7; p < 0.0001) than the healthy subjects (Figure 2). No difference was found in 
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the proportion of type I fibers (p = 0.65) between the CHF and healthy subjects (Figure 
2). However, type I fiber cross-sectional area (µm2) was lower in the CHF patient group 
than the healthy subjects (3026 ± 175 vs. 3681 ± 210; p < 0.05). No difference between 
groups was found in the cross-sectional areas of either type IIA or type IIX muscle fibers. 
 
Capillary Density. Capillary to fiber ratio was lower in CHF patients (p < 0.001) than in 
control subjects (Table 5). CHF patients exhibited fewer capillaries surrounding type I 
fibers (p < 0.001) and type IIX fibers (p < 0.05) than controls. A trend was observed for 
fewer capillaries surrounding type IIA fibers (p = 0.075) in CHF patients compared to 
healthy controls. However, when capillary density was determined per unit of muscle 
fiber cross-sectional area, there was no difference between CHF patients and control 
subjects (Table 5). There was no correlation between capillary to fiber ratio and &VO2 peak 
in either the CHF patients (r = 0.24; p = 0.43) or the healthy control group (r = 0.14; p = 
0.76). Neither was there a correlation between capillary to fiber ratio and muscle strength 
in either the CHF patients (r = 0. 008, p = 0.98) or healthy subjects (r = 0.34, p = 0.50). 
 
DEXA. No difference was found between the CHF patients and the normal controls in 
either lean body mass or lean thigh mass (Table 6). There was a significant correlation 
between thigh lean mass and &VO2 peak for the CHF patients but this did not reach 
statistical significance in the healthy subjects (Figure 3). Additionally whole body lean 
mass was also significantly correlated with &VO2 peak  (r = 0.713; p<0.05) in CHF patients 
but again this did not reach significance in healthy subjects. 
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DISCUSSION 
This is the first study to examine muscle oxidative capacity as measured by MAPR in 
CHF patients. The major finding of this study is that, notwithstanding a very significant 
difference in &VO2 peak, there is no difference in MAPR between CHF patients and 
similarly aged healthy individuals. Studies investigating the effects of CHF on the 
activity of mitochondrial enzymes in skeletal muscle have produced equivocal results. 
Significant reductions in the activity of citrate synthase (CS) 10-12, β-hydroxyacyl 
coenzyme A dehydrogenase (HAD) 13,14 and succinate dehydrogenase (SDH) 10,13 have 
been reported. Other studies have reported no differences in CS 13,14,29, HAD 11 and SDH 
29. Nevertheless nuclear magnetic resonance (NMR) studies of muscle metabolism in 
patients affected by CHF have found more rapid depletion of phosphocreatine (PCr) 
during exercise 27,28 and lower rates of PCr resynthesis 27 indicating reduced muscle 
oxidative function. Hence it is not clear which of the major metabolic pathways, if any, 
plays a significant role in reduced exercise tolerance in CHF patients. Therefore while 
oxidative function is impaired in vivo, the role of reduced muscle oxidative capacity as a 
causative factor in reduced exercise tolerance in CHF patients is less clear.  
 
The measurement of mitochondrial enzyme activity is at best an indirect indicator of 
muscle oxidative capacity and only provides information about single reactions in 
complex pathways.  In addition, maximal enzymatic activities are in general substantially 
in excess of in vivo maximal mitochondrial oxidative function 30. In contrast, the method 
of MAPR, used in the current study, is a direct and comprehensive assessment of muscle 
oxidative capacity across the entire range of metabolic energy producing pathways 19,31,32. 
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Previous studies have demonstrated that MAPR is strongly associated with &VO2 peak. It is 
higher in endurance trained individuals compared to sedentary subjects 19 and increases 
with endurance training 31,32. No studies to date have examined the effect of CHF on 
MAPR. Importantly, we found no difference between CHF patients and controls in 
MAPR in the presence of any substrate combination. Consistent with this obervation we 
also found no difference in the activity of the mitochondrial enzymes CS and HAD. 
Clearly the current study is not consistent with other published literature and such 
differences in the data may be due in part to differences in the severity of the condition 
and/or the duration for which the patient has suffered CHF. The CHF patients included in 
this study are representative of the patients with systolic heart failure who attend a heart 
failure clinic, not having been selected because of cachexia or severe functional 
impairment, neither those referred specifically for cardiac transplantation. This is 
reflected in the mean age 68±9 years with a mean LVEF 27±8% on gated blood pool 
scanning. Our observations demonstrate that the reduced maximal oxygen consumption 
in this cohort of CHF patients must be due to factors other than muscle oxidative 
capacity. 
 
Muscle fiber types. Muscle biopsy studies in CHF have consistently demonstrated 
changes in muscle histochemistry including a reduced capillary to fiber ratio 13 and an 
increase in type IIX fiber proportions at the expense of either type I 10,33 and / or type IIA 
muscle fibers 11,13. Significant muscle fiber atrophy 33 and reduced total muscle cross 
sectional areas 27 have also been reported in CHF patients. Alterations in fiber type 
proportions are a potential cause of the exercise intolerance in CHF. The proportion of 
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type IIA muscle fibers was lower and the proportion of type IIX fibers was higher in the 
CHF group in the current study. Paradoxically, the increased proportion of type IIX 
muscle fibers did not result in a lower muscle oxidative capacity in CHF. Bigard et al. 34 
however have demonstrated that muscle deconditioning induced by hindlimb suspension 
in rats results in slow to fast phenotype transitions without change in mitochondrial 
function. We conclude, therefore, that fiber type transformations do not necessarily result 
in reductions in overall muscle oxidative capacity. 
 
Capillary density. The major function of the capillary bed in skeletal muscle is to supply 
oxygen and nutrients to the muscle fibers. Endurance training stimulates an increase in 
capillary density in human subjects without heart failure 35,36 indicating a potential 
correlation between capillary density and peak. In the present study there was no 
correlation between peak and the capillary to muscle fiber ratio in the CHF group. 
This observation is supported by the findings of Duscha et al. 
&VO2
&VO2
13 who found no significant 
difference in capillary to fiber ratio between the most exercise-impaired CHF patients (< 
4 METS) and the normal control group. In the current study the capillary to fiber ratio 
and capillary contacts per fiber were lower in the CHF group in comparison to the healthy 
subjects.  
 
The current study highlights the importance of measuring capillary density as a function 
of muscle fiber size. When capillary density was calculated relative to fiber area 
(capillaries/mm2), no difference between the CHF patients and the healthy control 
subjects was observed. The implication of this finding is that capillary density is not a 
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factor in the reduced exercise tolerance in CHF patients. This finding is also supported by 
DeSousa and colleagues 37 who reported no difference in capillaries relative to fiber area 
between CHF and sham-operated rats in either oxidative (soleus) or glycolytic 
(gastrocnemius) muscles. 
 
Role of muscle mass in reduced exercise capacity. &VO2 peak (ml/min) was significantly 
correlated with lean thigh mass in the CHF patients but less so in the normal healthy 
controls (Figure 3). This relationship in CHF patients has previously been observed in 
larger patient groups. 38,39 This suggests that reduced muscle mass could be a determinant 
of the reduced exercise capacity in CHF. Although the mean lean thigh and lean body 
mass were lower in the CHF group compared to the healthy subjects, these differences 
did not reach statistical significance. Nevertheless, the CHF patients did have 
significantly smaller type I muscle fibers, a lower lean thigh mass to body mass ratio and 
reduced thigh muscle strength (Table 2). Previous studies using computerized 
tomography 39 and magnetic resonance imaging 27,40 have demonstrated smaller muscle 
cross sectional areas in CHF patients. The reduction in the cross-sectional area of the type 
I fibers suggests that the CHF patients might recruit type II muscle fibers at lower 
exercise intensities. Additionally, the CHF group had a significantly lower proportion of 
type IIA fibers indicating an earlier reliance on glycolytic type IIX fibers during the 
incremental exercise test. This conclusion is substantiated by the earlier onset of lactic 
acidosis in the CHF group.  
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While muscle mass might be contributing to the difference in exercise capacity between 
the groups, the difference in lean body mass is unlikely to account for all of the 
substantially lower peak&VO2  in the CHF patients compared to the healthy control subjects. 
 
Metabolic control. While our data demonstrate that skeletal muscle oxidative capacity is 
not reduced in our cohort of CHF patients it is possible that the rate of oxidative 
phosphorylation during exercise is reduced. In vivo studies using P-31 nuclear magnetic 
resonance (P-31 NMR) spectroscopy have demonstrated reduced phosphocreatine (PCr) 
resynthesis post-exercise in CHF patients 27,41. As PCr resynthesis is an oxidative process, 
this suggests an impaired rate of oxidative phosphorylation. Cohen-Solal et al. 41 also 
reported slower kinetics of recovery of oxygen consumption in CHF patients after 
exercise, further supporting an impaired rate of muscle oxidative metabolism. 
Additionally, the PCr concentration in muscle declines more rapidly during submaximal 
exercise in CHF patients indicating lower rates of oxidative phosphorylation for given 
absolute and relative submaximal exercise loads 6,42. Skeletal muscle pH also began to 
decline earlier during exercise indicating an earlier onset of glycolysis. This is consistent 
with the earlier onset of lactic acidosis which was observed in the current study. Clearly, 
whilst we provide evidence that skeletal muscle oxidative capacity is not reduced, 
oxidative phosphorylation during exercise is impaired in CHF. 
 
A number of factors may be responsible for reducing oxidative phosphorylation during 
exercise in CHF. Toussaint et al. 43 have shown reduced reactive hyperemic flow in the 
calf muscles of CHF patients along with slowed PCr recovery. The authors concluded 
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that oxidative ATP resynthesis is limited by reduced oxygen availability, the result of 
impaired blood flow.  
 
In oxidative, but not glycolytic muscle, elevated levels of creatine considerably enhance 
respiratory control by ADP. Hence, during exercise, mitochondrial respiration is 
stimulated by increased cytosolic creatine levels in oxidative but not glycolytic muscles. 
Consequently, fiber type alterations that increase glycolytic fiber proportions would 
reduce the sensitivity of whole muscle oxidative phosphorylation to ADP stimulation. 
The higher proportion of glycolytic fibers in CHF patients than in controls may explain 
the aforementioned lower levels of oxidative phosphorylation during exercise. 37 A 
further mechanism related to the control of oxidative phosphorylation during exercise, as 
described by Conley et al., 44 may also explain the lower exercise capacity of CHF 
patients. During exercise PCr levels fall and ADP levels rise as described by the creatine 
kinase equilibrium shown below  
 
PCr + ADP + H+ ↔ ATP + Cr 
 
The ADP level is the central signal for oxidative phosphorylation. Conley et al. 44 point 
out that the rise in ADP as PCr levels fall is attenuated at lower intramuscular pH. In our 
CHF group we observed higher proportions of type IIX glycolytic muscle fibers and an 
earlier onset of lactic acidosis in incremental exercise potentially reflecting a lower 
muscle pH. We postulate, therefore, that the rate of rise of ADP in the CHF group and the 
rate of oxidative phosphorylation during incremental exercise would be less than that in 
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the controls leading to a greater reliance on glycolytic ATP production. In support of this 
claim Massie et al. 6 have observed a lower muscle pH during submaximal exercise in 
CHF patients compared to healthy control subjects.  
 
Conclusions. The major finding of this study was that there was no difference between 
CHF patients and healthy control subjects in skeletal muscle MAPR across the full range 
of substrates. Neither was there impaired activity of the muscle oxidative enzymes 
investigated. Therefore the CHF patients in this study, who are generally older and 
perhaps more representative of CHF patients in the general community than those 
described in previous studies, appear to have normal resting skeletal muscle oxidative 
function, although impaired oxidative phosphorylation during exercise cannot be 
excluded.  
 
Capillary density is reduced in these CHF patients in association with muscle fiber 
atrophy. However, the reduced peak&VO2  does not appear to be associated with this 
reduction in capillary density. 
 
Lower lean body mass and type I fiber atrophy are both associated with the impairment in 
peak&VO2 . It is unclear whether or not these morphological changes in skeletal muscle 
might be reversible following muscle-strengthening exercise training and/or better 
treatment of the underlying heart failure. 
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Figure 1. Mitochondrial ATP Production Rate in Patients With Class II-III CHF and 
Healthy Subjects (Mean ± SEM). The substrate combinations were: P+M = pyruvate + 
malate; PC+M = palmitoyl-L-carnitine + malate; α-KG = α-ketoglutarate; S+R = 
succinate + rotenone; PPKM = pyruvate + palmitoyl-L-carnitine + α-ketoglutarate + 
malate. CHF = chronic heart failure. 
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Figure 2. Skeletal Muscle Fiber Type Proportions in CHF Patients and Healthy Subjects 
# denotes p < 0.0001. CHF = chronic heart failure. 
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Figure 3. Correlations between Lean Thigh Mass and VO2 peak for 11 CHF and 8 
Healthy Controls. CHF = chronic heart failure. 
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 Table 1. Descriptive characteristics of the 14 CHF patients (Mean ± S.D.) 
 
 CHF patients (n=14) 
CHF diagnosis  
Ischemic heart disease 8 (57%) 
Dilated cardiomyopathy 5 (36%) 
Valvular 1 (7%) 
Medications  
Angiotensin converting enzyme inhibitor  11 (79%) 
Angiotensin receptor blocker 3 (21%) 
Diuretic 13 (93%) 
Beta-blocker 6 (43%) 
Digoxin 6 (43%) 
Aspirin 11 (79%) 
Warfarin 4 (29%) 
Amiodarone 2 (14%) 
Nitrates 7 (50%) 
Calcium channel antagonist 2 (14%) 
 
 
Table 2. Skeletal muscle strength and peak data for CHF patients and Healthy 
subjects 
&VO2
 CHF Healthy 
&VO2 peak (ml.kg-1.min-1) 15.1 ± 1.1 28.1 ± 2.3‡
% Predicted peak &VO2 64 ± 4 111 ± 9‡
Knee Extension (Nm) 105 ± 11 133 ± 6* 
Knee Flexion (Nm) 45 ± 5 64 ± 4†
*Denotes p < 0.05. †Denotes p < 0.01. ‡Denotes p < 0.001. 
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 Table 3. Plasma Lactate and Workload Data for CHF Patients and Healthy Subjects 
 CHF Healthy 
Peak Watts 64 ± 7 134 ± 14†
Lactate at fatigue (mmol/L) 4.6 ± 0.6 8.2 ± 0.9†
Lactate Threshold (W) 30.3 ± 3.5 81.6 ± 8.6‡
Lactate Threshold/ Peak Watts (%) 49.1 ± 2.7 61.7 ± 3.3†
Peak Respiratory Exchange Ratio 
(RER) 
1.12 ± 0.04 1.16 ± 0.03 
†Denotes p < 0.01. ‡Denotes p < 0.001. 
 
Table 4. Skeletal Muscle Enzyme Activity in Patients With Class II-III CHF and Healthy 
Subjects (µmol/min/g WW) 
Enzyme CHF Healthy 
Citrate Synthase 14.43 ± 1.02 14.63 ± 0.85 
β-Hydroxyacyl-CoA Dehydrogenase 13.06 ± 0.89 13.58 ± 1.25 
Phosphofructokinase 29.80 ± 1.17 27.47 ± 1.13 
Lactate Dehydrogenase 60.29 ± 8.89 79.75 ± 13.69 
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Table 5. Skeletal Muscle Capillary Density in CHF Patients and Healthy Subjects 
 CHF Healthy (n=7) 
Capillary to Fiber Ratio 1.09 ± 0.05 1.40 ± 0.04†
Capillaries Contacting 
Individual Fibers 
  
Type I 3.02 ± 0.13 3.82 ± 0.11†
Type IIA 2.71 ± 0.15 3.06 ± 0.10 
Type IIB 2.14 ± 0.11 2.46 ± 0.08*
Capillaries per mm2 of fiber 
area 
  
Type I 1147 ± 85 1122 ± 87 
Type IIA 1038 ± 45 1082 ± 65 
Type IIB 1017 ± 58 1118 ± 100 
*Denotes p < 0.05. †Denotes p < 0.001.  
 
Table 6. Total Body and Thigh Lean Masses and Lean Thigh/Total Body Mass Ratio in 
CHF Patients (n = 11) and Healthy Subjects  
 CHF Healthy 
Lean Thigh Mass (kg) 5.34 ± 0.30 5.87 ± 0.31 
Lean Body Mass (kg) 50.79 ± 2.31 52.83 ± 2.43 
Lean Thigh/Body Mass % 6.97 ± 0.24 8.01 ± 0.34*
*Denotes p < 0.05.  
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